The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1377
Sitagliptin and Simvastatin (Juvisync)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).

ACTIVITY — Statins have been shown to lower the risk of cardiovascular disease in patients with diabetes, even though they may cause small increases in glycated hemoglobin (A1C) and fasting blood glucose levels.1 DPP-4 inhibitors are generally used as alternatives to a sulfonylurea or pioglitazone (Actos) for addition to metformin (Glucophage, and others) in patients who do not achieve their A1C goal with metformin alone; the addition of a DPP-4 inhibitor modestly reduces A1C (0.5-0.8%) and appears to be well tolerated, but the long-term safety of these agents remains to be established.

DOSAGE AND COSTJuvisync ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sitagliptin and Simvastatin (Juvisync)
Article code: 1377a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian